Beilstein Journal of Organic Chemistry p. 155 - 161 (2015)
Update date:2022-08-16
Topics:
Johannes, Manuel
Reindl, Maximilian
Gerlitzki, Bastian
Schmitt, Edgar
Hoffmann-R?der, Anja
The development of selective anticancer vaccines that provide enhanced protection against tumor recurrence and metastasis has been the subject of intense research in the scientific community. The tumor-associated glycoprotein MUC1 represents a well-established target for cancer immunotherapy and has been used for the construction of various synthetic vaccine candidates. However, many of these vaccine prototypes suffer from an inherent low immunogenicity and are susceptible to rapid in vivo degradation. To overcome these drawbacks, novel fluorinated MUC1 glycopeptide-BSA/TTox conjugate vaccines have been prepared. Immunization of mice with the 4'F-TF-MUC1-TTox conjugate resulted in strong immune responses overriding the natural tolerance against MUC1 and producing selective IgG antibodies that are cross-reactive with native MUC1 epitopes on MCF-7 human cancer cells.
View MoreZIBO ZEYUAN IMPORT & EXPORT CO.,LTD
Contact:+86-533-6723789
Address:Zhangdian District Youth League West Blue Diamond International 408 121
Xi'an North Information Industry Co., Ltd. Weilv Chemical Department
Contact:+86-29-88156413
Address:Jixiang Road 99 Xi'an Shaanxi Province
Xiamen Kaijia Imp & Exp Co., Ltd.
Contact:86-592-5101177
Address:Room406 Luhui Building No. 65 Haitian Road Huli Xiamen,China.
ShangHai Ruiyi Medical Technology Co.,Ltd.
Contact:+86-21-54718086
Address:No951 Jianchuan RD,Minhang District
Huangshan Violet Biological Technology Co., Ltd
Contact:+86-559-2335676
Address:16-201 JinShanYuan,JiangNan New City,TunXi District,HuangShan City,AnHui Province,China
Doi:10.1021/jo00341a018
(1982)Doi:10.1007/s10562-011-0731-y
(2012)Doi:10.1016/S0040-4039(01)92754-6
(1977)Doi:10.1021/ja00344a022
(1983)Doi:10.1002/jps.2600771014
(1988)Doi:10.1002/anie.201006870
(2011)